Charles River (CRL) | Financial Analysis & Statements
Charles River Laboratories International, Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
994.2M
Gross Profit
309.7M
31.15%
Operating Income
92.5M
9.31%
Net Income
-276.3M
-27.79%
EPS (Diluted)
$-5.62
Balance Sheet Metrics
Total Assets
7.1B
Total Liabilities
3.9B
Shareholders Equity
3.2B
Debt to Equity
1.22
Cash Flow Metrics
Operating Cash Flow
-232.0M
Free Cash Flow
58.6M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Charles River Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 4.0B | 4.0B | 4.1B | 4.0B | 3.5B |
| Cost of Goods Sold | 2.7B | 2.7B | 2.6B | 2.5B | 2.2B |
| Gross Profit | 1.3B | 1.3B | 1.5B | 1.5B | 1.3B |
| Gross Margin % | 33.0% | 32.9% | 36.4% | 36.8% | 37.7% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 743.1M | 751.0M | 747.9M | 665.1M | 619.9M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 743.1M | 751.0M | 747.9M | 665.1M | 619.9M |
| Operating Income | 401.1M | 442.3M | 617.3M | 651.0M | 589.9M |
| Operating Margin % | 10.0% | 10.9% | 14.9% | 16.4% | 16.7% |
| Non-Operating Items | |||||
| Interest Income | 4.9M | 8.6M | 5.2M | 780.0K | 652.0K |
| Interest Expense | 107.0M | 126.3M | 136.7M | 59.3M | 73.9M |
| Other Non-Operating Income | -398.6M | -231.5M | 95.5M | 30.5M | -35.9M |
| Pre-tax Income | -99.5M | 93.1M | 581.3M | 623.0M | 480.7M |
| Income Tax | 42.7M | 67.8M | 100.9M | 130.4M | 81.9M |
| Effective Tax Rate % | 0.0% | 72.8% | 17.4% | 20.9% | 17.0% |
| Net Income | -142.2M | 25.3M | 480.4M | 492.6M | 398.8M |
| Net Margin % | -3.5% | 0.6% | 11.6% | 12.4% | 11.3% |
| Key Metrics | |||||
| EBITDA | 786.8M | 796.1M | 1.0B | 986.1M | 820.2M |
| EPS (Basic) | $-2.91 | $0.20 | $9.27 | $9.57 | $7.77 |
| EPS (Diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
| Basic Shares Outstanding | 49564000 | 51380000 | 51227000 | 50812000 | 50293000 |
| Diluted Shares Outstanding | 49564000 | 51380000 | 51227000 | 50812000 | 50293000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Charles River Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 213.8M | 194.6M | 276.8M | 233.9M | 241.2M |
| Short-term Investments | - | - | - | - | 1.1M |
| Accounts Receivable | 518.7M | 527.7M | 578.1M | 559.4M | 489.5M |
| Inventory | 299.1M | 278.5M | 380.3M | 255.8M | 199.1M |
| Other Current Assets | 129.2M | 105.8M | 83.4M | 107.6M | 97.3M |
| Total Current Assets | 1.4B | 1.4B | 1.6B | 1.4B | 1.3B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 361.4M | 412.5M | 394.0M | 391.8M | 292.9M |
| Goodwill | 5.9B | 6.4B | 7.1B | 6.7B | 6.5B |
| Intangible Assets | 340.0M | 723.4M | 864.1M | 955.3M | 1.1B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 360.5M | 320.4M | 349.7M | 189.5M | 210.5M |
| Total Non-Current Assets | 5.7B | 6.1B | 6.6B | 6.2B | 5.8B |
| Total Assets | 7.1B | 7.5B | 8.2B | 7.6B | 7.0B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 148.8M | 140.3M | 168.9M | 205.9M | 198.1M |
| Short-term Debt | - | - | - | - | 36.1M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 222.2M | 194.0M | 203.2M | 204.6M | 140.4M |
| Total Current Liabilities | 1.1B | 994.1M | 1.1B | 1.1B | 1.0B |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.6B | 2.7B | 3.1B | 3.1B | 2.9B |
| Deferred Tax Liabilities | 95.2M | 107.0M | 191.3M | 215.6M | 239.7M |
| Other Non-Current Liabilities | 138.3M | 195.2M | 223.2M | 174.8M | 242.9M |
| Total Non-Current Liabilities | 2.8B | 3.0B | 3.5B | 3.5B | 3.4B |
| Total Liabilities | 3.9B | 4.0B | 4.5B | 4.6B | 4.4B |
| Equity | |||||
| Common Stock | 492.0K | 511.0K | 513.0K | 509.0K | 505.0K |
| Retained Earnings | 1.4B | 1.8B | 1.9B | 1.4B | 980.8M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 3.2B | 3.5B | 3.7B | 3.0B | 2.6B |
| Key Metrics | |||||
| Total Debt | 2.6B | 2.7B | 3.1B | 3.1B | 3.0B |
| Working Capital | 326.7M | 409.0M | 553.6M | 347.4M | 240.9M |
Balance Sheet Composition
Charles River Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -142.2M | 25.3M | 480.4M | 492.6M | 398.8M |
| Depreciation & Amortization | 403.3M | 361.7M | 314.1M | 303.9M | 265.5M |
| Stock-Based Compensation | 71.1M | 69.9M | 72.0M | 73.6M | 71.5M |
| Working Capital Changes | -65.2M | -2.7M | -114.8M | -110.4M | -1.4M |
| Operating Cash Flow | 194.2M | 420.0M | 704.2M | 741.8M | 678.7M |
| Investing Activities | |||||
| Capital Expenditures | - | - | - | - | - |
| Acquisitions | 17.4M | -5.5M | -194.8M | -120.1M | -1.2B |
| Investment Purchases | -20.1M | -52.9M | -54.2M | -158.3M | -45.6M |
| Investment Sales | 9.1M | 41.7M | 6.7M | 4.5M | 6.5M |
| Investing Cash Flow | 9.8M | -12.1M | -244.6M | -283.2M | -1.2B |
| Financing Activities | |||||
| Share Repurchases | -360.7M | -119.2M | -24.2M | -38.7M | -40.7M |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 1.2B | 1.1B | 776.4M | 3.0B | 7.0B |
| Debt Repayment | -1.3B | -1.5B | -851.7M | -2.9B | -6.3B |
| Financing Cash Flow | -537.4M | -574.8M | -111.1M | -67.5M | 626.9M |
| Free Cash Flow | 518.5M | 501.6M | 365.4M | 294.9M | 532.0M |
| Net Change in Cash | -333.4M | -166.9M | 348.5M | 391.1M | 96.5M |
Cash Flow Trend
Charles River Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
681.33
Forward P/E
13.59
Price to Book
2.61
Price to Sales
2.06
PEG Ratio
20.54
Profitability Ratios
Profit Margin
-3.60%
Operating Margin
4.51%
Return on Equity
-4.23%
Return on Assets
4.24%
Financial Health
Current Ratio
1.29
Debt to Equity
81.95
Beta
1.62
Per Share Data
EPS (TTM)
$-2.90
Book Value per Share
$64.30
Revenue per Share
$81.01
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| CRL | 8.3B | 681.33 | 2.61 | -4.23% | -3.60% | 81.95 |
| Thermo Fisher | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| Revvity | 9.7B | 45.77 | 1.46 | 3.22% | 8.45% | 46.87 |
| Icon plc | 9.0B | 15.52 | 0.94 | 6.27% | 7.40% | 38.26 |
| Qiagen N.V | 7.9B | 18.76 | 2.09 | 11.57% | 20.33% | 48.56 |
Financial data is updated regularly. All figures are in the company's reporting currency.





